EUVIMEDAtklāt EUVIMED
CrossrefInformācijas karte

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, Jan C. Hofmann, Reinhard Klingel, Oluwatoyosi A. Onwuemene, Christopher J. Patriquin, Huy P. Pham, Amber P. Sanchez, Jennifer Schneiderman, Volker Witt, Nicole D. Zantek, Nancy M. Dunbar

Journal of Clinical Apheresis · 2023-04 · 38 (2) · 77-278

DOI: 10.1002/jca.22043 ↗
AbstraktsBibliogrāfiskie dati

Abstrakts

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence‐based use of therapeutic apheresis (TA) in human disease. In the Ninth Edition, the JCA Special Issue Writing Committee has incorporated systematic review and evidence‐based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease or medical condition. The Ninth Edition of the JCA Special Issue comprises 91 fact sheets and 166 graded and categorized indications. This includes seven new fact sheets, nine new indications on existing fact sheets, and eight changes in the category for existing indications. The Ninth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.

Jūsu darbam piemērotas zināšanas.

No bezmaksas sākuma un personīgās literatūras meklēšanas līdz pilnam Research Suite.

Skatīt tarifus →

Vai ir iekļauti visi izdevēju pilnteksti?

Nē. Bibliogrāfiskie ieraksti, kopsavilkumi un pilnteksti ir atšķirīgs saturs. Tas, vai pilnteksts ir pieejams, ir atkarīgs no avota, Open Access un jūsu esošajām licencēm. EUVIMED tarifs neaizstāj papildu izdevēju tiesības.

Skatīt tarifus →